May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
The IOL–Vip® system. A new double–IOL intraocular device for visual rehabilitation in patients with cataract and macular degeneration. A pilot study.
Author Affiliations & Notes
  • C.O. Pierrottet
    University Eye Clinic, San Paolo Hospital, Milan, Italy
    Retinitis Association, Milan, Italy
  • G. Savaresi
    University Eye Clinic, San Paolo Hospital, Milan, Italy
    Retinitis Association, Milan, Italy
  • N. Orzalesi
    University Eye Clinic, San Paolo Hospital, Milan, Italy
  • Footnotes
    Commercial Relationships  C.O. Pierrottet, None; G. Savaresi, None; N. Orzalesi, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3737. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.O. Pierrottet, G. Savaresi, N. Orzalesi; The IOL–Vip® system. A new double–IOL intraocular device for visual rehabilitation in patients with cataract and macular degeneration. A pilot study. . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3737.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To establish the efficacy and tolerance of a new intraocular magnifying device (IOL–Vip® (Visually Impaired People) System) in patients with cataract and low vision due to macular degeneration. Methods: 11 patients (age range 57–82 years) with different forms of macular degeneration (6 disciform scars or atrophic AMD, 2 myopic macular degeneration, 1 macular hole, 1 disciform scar in angioid streaks and 1 Stargardt’s disease) underwent facoemulsification with the implant of the IOL–Vip® system. This double–IOL system is made of a negative biconcave IOL to be put in the capsular bag and a positive biconvex IOL to be put in the anterior chamber. It reproduces a sort of Galilean telescope with 1.3X magnification for distance. Suitability for the surgical implant was established in all cases with functional and ocular evaluation, by means of the IOL–Vip® dedicated software, which estimates distance and near best corrected visual acuity, Preferred Retinal Locus (PRL) (objective and subjective), visual improvement with simulation of the magnifying effect of the IOL–Vip® system. The IOL–Vip® software also indicates the rehabilitation training program for the PRL, before and after surgery. Results: Follow–up visits were performed every three months and all the patients were followed for at least one year. The system was well tolerated, but in 9 patients a YAG laser iridotomy was performed to avoid pupillary block (6 pre–op and 3 post–op). All the patients, except one, showed visual acuity improvement, assessed with the Subvision charts, as well as an improvement of daily living activities. Conclusions: This pilot study shows that IOL–Vip® system represents a safe and effective surgical procedure for patients with low vision due to macular conditions. The low magnifying effect, induced by the IOL–Vip® system, does not limit the peripheral visual field and patients can retain binocular vision. Other clinical studies are recommended.

Keywords: low vision • cataract • age–related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×